Literature Review of Studies Evaluating Cost Effectiveness of Prostaglandins and ß-Blockers in Primary Open Angle Glaucoma Patients

Abstract

A569data. Results were presented as incremental cost-effectiveness ratios (ICERs) per PASI90 16-week response. Both one-way and probabilistic sensitivity analyses were performed to test the robustness of the results. Results: Combining Secukinumab 300 significantly greater effectiveness in terms of PASI90 response compared with Ustekinumab and Etanercept with the total 2-year costs accrued in each therapeutic option, the base-case ICERs per PASI90 response of Secukinumab 300 versus Ustekinumab 90, Ustekinumab 45, Ustekinumab 90&45 weighted and Etanercept were € 9,543, € 13,316, € 11,941 and € 17,448, respectively. These ICERs lie well beneath the defined willingness-to-pay threshold of € 36,000 in Greece (twice the per capita income) indicating that Secukinumab 300 is cost-effective versus Ustekinumab and Etanercept in moderate-to-severe plaque psoriasis. The sensitivity analyses confirmed the robustness of the model results. ConClusions: Secukinumab was found to be cost-effective in terms of PASI90 response at 16-weeks compared with both Ustekinumab and Etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece.